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Abstract
Background: Drug resistance levels and patterns among Mycobacterium tuberculosis isolates from newly diagnosed
and previously treated tuberculosis patients in Mbarara Uganda were investigated.
Methods: We enrolled, consecutively, all newly diagnosed and previously treated smear-positive TB patients aged
≥ 18 years. Isolates were tested for drug resistance against rifampicin (RIF) and isoniazid (INH) using the Genotype®
MDRTBplus assay and results were compared with those obtained by the indirect proportion method on
Lowenstein-Jensen media. HIV testing was performed using two rapid HIV tests.
Results: A total of 125 isolates from 167 TB suspects with a mean age 33.7 years and HIV prevalence of 67.9%
(55/81) were analysed. A majority (92.8%) of the participants were newly presenting while only 7.2% were
retreatment cases. Resistance mutations to either RIF or INH were detected in 6.4% of the total isolates. Multidrug
resistance, INH and RIF resistance was 1.6%, 3.2% and 4.8%, respectively. The rpob gene mutations seen in the
sample were D516V, S531L, H526Y H526 D and D516V, while one strain had a Δ1 mutation in the wild type probes.
There were three strains with katG (codon 315) gene mutations while only one strain showed the inhA promoter
region gene mutation.
Conclusion: The TB resistance rate in Mbarara is relatively low. The GenoType® MTBDRplus assay can be used for
rapid screening of MDR-TB in this setting.
Background
Despite the availability of drugs to treat tuberculosis
(TB), it remains the world’s leading cause of death from
a single infectious disease. The World Health Organiza-
tion (WHO) estimates current rates of multidrug resis-
tant TB (resistance to at least isoniazid and rifampicin)
in new and previously treated cases globally at 2.9% and
15.3% respectively, with 57% of multidrug resistant
tuberculosis (MDR-TB) cases coming from three high
burden countries (China, India, and the Russian Federa-
tion) [1].
Uganda is currently ranked 16
th among the highest TB
burdened countries in the world [2]. The prevalence of
MDR-TB in new cases in this setting has previously
been reported to be low at less than 2% [3]. However,
there are recent reports that 12.7% of re-treatment cases
attending the National Tuberculosis and Leprosy Pro-
gram (NTLP) clinic in Kampala, the capital city of
Uganda, had MDR-TB [4] and that in one peri-urban
population of Kampala the prevalence of MDR-TB was
4.4% in new cases [5]. Although drug susceptibility test-
ing is not routinely undertaken in Uganda it would be
advantageous to know the drug susceptibility status
especially of re-treatment patients to facilitate appropri-
ate patient management.
Several competing technologies have been proposed
for rapid detection of drug resistant tuberculosis. Some
commercial assays are currently available including
INNO-LiPA Rif.TB (Innogenetics N.V, Ghent, Belgium)
and GenoType® MTBDR (HAIN Lifesciences GmbH,
Nehren, Germany) [6]. The new version of the latter
assay (GenoType® MTBDRplus), targeting the rpoB gene
associated with the resistance to rifampicin (RIF) and
both genes (katG and inhA) commonly associated with
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mainly on cultures and clinical specimens in various low
incidence settings, demonstrating excellent specificity
and good concordance with phenotypic drug susceptibil-
ity test (DST) results [7,8]. A recent study demonstrated
the feasibility of this assay as a screening tool when
applied in a high-volume public health laboratory in a
high TB and HIV, but low drug resistance, incidence
area [8].
This study aimed at determining the levels and pat-
terns of anti-TB drug resistance to the two key drugs
(rifampicin and isoniazid) in M. tuberculosis strains iso-
l a t e df r o mT Bp a t i e n t sf r o mt h er u r a ls e t t i n go fM b a r -
ara, South-Western Uganda, using the commercially
available GenoType® MTBDRplus assay.
Methods
Study setting
Sampling for this study was conducted between May
2007 and April 2008 in Mbarara, South- Western
Uganda. This is the second most TB burdened area in
the country, with an estimated TB/HIV co-infection rate
of 65% [9].
Study design
This was a cross sectional study in which all smear-posi-
tive newly diagnosed and retreatment TB patients aged
≥ 18 years presenting at the various TB clinics in the
greater Mbarara area during the study period were
enrolled. Three consecutive sputum samples (spot, early
morning and spot) were taken from each patient accord-
ing the Uganda National TB and Leprosy Programme
(NTLP) guidelines. Samples were stored at 4°C at the
recruitment clinics, in any case for not more than 48
hours, until transported in a cold box to the National
TB Reference Laboratory (NTRL) in Kampala for pro-
cessing and culture.
Sample processing and culture
Specimens (2.5-10 ml) were processed by the standard
N-acetyl L-cystein (NALC)-NaOH method [10] and
concentrated by centrifuging at 4000 × g for 15 minutes.
The sediment was reconstituted to 2.5 ml using a phos-
phate buffer (pH 6.8), to make the inoculum for the
smears and cultures. Two Lowenstein-Jensen slants, one
containing 0.75% glycerol and the other containing 0.6%
pyruvate, were inoculated with the sediment and incu-
bated at 37°C and examined weekly for growth. Cultures
were considered negative when no colonies were seen
after 8 weeks incubation.
GenoType® MTBDRplus assays
Identification of mutations in rpoB, katG, genes and the
inhA promoter region associated with resistance to RIF
and INH was performed on the mycobacterial cultures
according to the manufacturer’s recommendations.
Briefly, heat thermolysates of cultures were obtained by
heating cultures suspended in Tris-EDTA (TE) at 80°C
f o rt w oh o u r sf o l l o w e db yi n c u b a t i o ni na nu l t r a s o n i c
bath for 5 minutes. Polymerase chain reaction (PCR)
and subsequent hybridization steps were performed
according to manufacturer’s recommendations. There-
after, strips were attached to the evaluation sheet, read
and interpreted. For quality control we included known
fully susceptible and resistant isolates in each run.
Conventional drug susceptibility testing
The indirect proportion method on Lowenstein-Jensen
media was performed by the NTLP for patient manage-
ment at the following final drug concentrations: rifampi-
cin, 40 μg/ml and isoniazid, 0.2 μg/ml. The NTLP
kindly provided the results for comparison with the kit
results.
HIV testing
HIV-1 testing was performed using two rapid HIV tests,
Unigold Recombinant HIV (Trinity Biotech, Wicklow,
Ireland) and Determine HIV-1/2 (Abbott, Tokyo, Japan).
Samples were tested first with Abbot Determine and
reported only when negative. Positive samples were con-
firmed with Unigold, while discordant results were
resolved by a third rapid test kit, HIV-1/2 Stat-Pak
(ChemBio, Medford, NY). Pre and post test counselling
was done for all consenting individuals.
Ethical considerations
This study received ethical clearance from the research
and ethics committee of the faculty of medicine of
Mbarara University of Science and Technology, the
Institutional Review Board of Mbarara University of
Science and Technology and the National Council for
Science and Technology. Patients were identified and
managed according to Uganda NTLP guidelines [11].
Informed consent to participate in the study as well as
permission to use isolates from samples provided were
obtained from all participants before enrolment.
Results
Study population and samples
We enrolled a total of 167 sputum smear positive TB sus-
pects presenting at the various TB clinics in the greater
Mbarara during the study period. The samples were
graded depending on AFB count in the specimen accord-
ing to the WHO recommendations [12]. Of the 167 sam-
ples that were cultured 140 (83.8%) showed growth after
eight weeks of incubation, 14 (8.4%) had no growth while
13 (7.8%) were contaminated. Of the 140 isolates, 15
(10.7%) were from patients whose socio-demographic data
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125 isolates for molecular analysis. Of the 125 patients in
the molecular study, majority 116 (92.8%) were newly
diagnosed while only 9 (7.2%) had a previous history of TB
treatment. The proportion of female patients was 40%
(50/125) while that of males was 60% (75/125). The mean
age of the study patients was 33.7 years. HIV results were
available for only 81 patients who consented to testing, of
whom 67.9% (55/81) were HIV sero-positive.
Drug susceptibility results
Susceptibility testing using the GenoType® MTBDRplus
assay showed that a total of 6/125 (4.8%) isolates were
resistant to INH, 4 (3.2%) resistant to RIF, while
2 (1.6%) of these isolates were resistant to both INH
and RIF (MDR). Both MDR isolates were from HIV-
infected female patients less than 39 years of age with
new TB. A summary of patient demographic character-
istics and associated drug susceptibility pattern is shown
in Table 1. There was no statistical relationship between
clinical and epidemiologic characteristics and anti-TB
susceptibility in the study.
Mutations associated with RIF and INH resistance using
the GenoType® MTBDRplus assay
Mutations conferring resistance to either rifampicin or
isoniazid were detected in 8/125 (6.4%) of samples
analyzed. In all, six isolates were resistant to rifampicin,
two of which showed mutation in katG gene and/or
inhA promoter region indicating that they were INH
resistant, hence MDR (Table 2). The rifampicin resistant
isolates displayed three types of mutations: three isolates
had a mutation at position D516V, two had S531L,
while one of the isolates with D516V had a further two
mutations, H526Y and H526 D in the rpob gene. Only
one strain had a Δ1 mutation in the wild type probes
and, according to the kit manufacturer’s recommenda-
tion, was considered resistant. Four isolates showed
resistance to isoniazid (Table 2). Mutations associated
with isoniazid resistance were less compared to those
seen in rifampicin resistance, with three strains having
mutations in the katG (codon 315) gene only while one
strain had a mutation in the inhA gene only (position
(-15) in the mabA-inhA promoter). All KatG wild type
positive probes also had mutant probes being positive,
as was the case with the single inhA mutant. Only one
isolate resistant to rifampicin showed a double pattern
while all four isoniazid resistant strains showed double
patterns (three in the KatG probes and the other in the
inhA probes). Additionally, one strain showing resis-
tance to rifampicin by the proportion method on Low-
enstein-Jensen media did not display a similar genotype
even on repeat assay (isolate 102, Table 2).
Discussion
I nt h ec u r r e n ts t u d yw eh a v ed e t e r m i n e dt h el e v e l sa n d
patterns of anti-TB drug resistance to the two key anti-
tuberculosis drugs (rifampin and isoniazid) in M. tubercu-
losis strains isolated from patients from the rural setting of
Mbarara, South-Western Uganda, using a line probe tech-
nique, the commercially available GenoType® MTBDRplus
assay. This technique may thus prove suitable for use in a
majority of diagnostic laboratories in TB endemic coun-
tries which do not have the capacity to undertake culture
and drug susceptibility testing of M. tuberculosis.
We found resistance to isoniazid and rifampicin, to
be 3.2% and 5.6% respectively, while MDR was 1.6%
(2/125). Our result show differences compared with find-
ings that were obtained in a previous National anti-tuber-
culosis drug resistance survey in Uganda of 1996-97 that
indicated a primary resistance to isoniazid of 6.7%, that
to rifampicin at 0.8%, and MDR of 0.5% [13]. More
recently, a study in Peri-urban Kampala showed resis-
tance to isoniazid of 8.1%, rifampicin resistance of 4.4%
and MDR was found to be 4.4% [5]. These differences
may probably be due to sampling strategy employed in
each study. While the National survey randomly sampled
districts in Uganda, the peri-urban study in Kampala
looked at a single division known to be the second most
TB burdened in the city, while the current study sampled
patients from various villages of a rural district in western
Table 1 Comparison of clinical and epidemiologic
characteristics of the patients with isolates resistant to
isoniazid and rifampicin by the GenoType® MTBDRplus
assay
Drug susptibility pattern
Characteristic Number of
patients
INH
a RIF
b MDR
c
Age
< 39 years 96 2 3 2
40-60 years 27 0 1 0
> 60 years 2 0 0 0
Gender
Male 75 0 2 0
Female 50 2 2 2
TB history
New 116 1 3 2
Retreatment 9 1 1 0
HIV status
Positive 55 1 1 2
Negative 26 0 1 0
Unknown 44 1 2 0
Smear result
1-10/10-100HPF 30 0 1 1
> 1AFB/HPF 95 2 3 1
aMonoresistance to isoniazid;
bMonoresistance to rifampicin;
cResistance to
both isoniazid and rifampicin.
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rifampicin is a surrogate marker for MDRTB, this study
observed a high rate of monoresistance to rifampicin.
The low sensitivity of the assay for detection of isoniazid
resistance is likely due to the fact that the assay targets
only katG315 mutations while isoniazid resistance in M.
tuberculosis strains could also involve mutations in other
katG gene regions or in other loci. For example, muta-
tions in the inhA promoter region occur in 15% to 35%
of INH-resistant M. tuberculosis strains from some geo-
graphical locations. Another interesting observation was
a higher rate of resistance amongst female patients (6/50;
12%) compared to males (2/75; 2.7%), although not quite
reaching significance. This might be related to health
seeking behavior, with prolonged delays in female
patients (probably due to lack of control of financial
resources at household levels) as has been observed by
Oola [14] in Mukono district, another rural setting in
Central Uganda.
Studies from neighbouring East African countries
show varied results. In the only recorded study in
Rwanda, resistance to isoniazid was found at 6.2%, that
to rifampicin was 3.9% with all rifampicin resistant iso-
lates being multidrug-resistant [15]. In northern Tanza-
nia, on the other hand, a study of 111 isolates showed
that 9.9% were resistant to isoniazid, 2.7% to rifampicin,
while MDR was 2.7% [16]. Generally, the drug resistance
rates in the current study are fairly within the range of
those found in previous studies both in-country and
around the region. However there is evidence of an
increase in the MDR rate in Uganda in the last two stu-
dies compared to the first National survey albeit on a
smaller sample. Although a number of patients were not
tested for HIV and could be dually infected, two thirds
of those tested were co-infected with both HIV and TB,
and this is a common trend in sub Saharan Africa [17].
In the sample analyzed, GenoType® MTBDRplus
results indicated one isolate resistant to rifampicin
h a v i n gad o u b l ep a t t e r n( p o s i t i v eh y b r i d i z a t i o nw i t h
mutant and wild type probes), while all four isoniazid
resistant strains showed double patterns (three in the
KatG probes and the other in the inhA probes). The
double patterns are thought to be due to heteroresis-
tance, i.e simultaneous presence of both drug resistant
and susceptible TB bacilli in samples as has been
hypothesized elsewhere [18]. It has also been reported
that heteroresistance is an important factor which can
affect the accuracy and reliability of drug susceptibility
testing results by line probe assays and maybe a reason
for double patterns on GenoType® MTBDRplus mem-
branes [7,19]. Heteroresistance is more likely to occur in
high TB incidence areas and in cultures isolated from
c h r o n i cp a t i e n t sa st h e yh a v em o r eo p p o r t u n i t yt o
become infected with various populations of mycobac-
teria [20] as is the likely scenario in our setting.
Conclusion
The M. tuberculosis resistance rate in Mbarara is rela-
tively low. Additionally, weh a v ed e m o n s t r a t e dt h a tt h e
GenoType® MTBDRplus assay can be used for rapid
screening of MDR-TB in this setting. However, muta-
tion regions of the rpob and KatG genes that are not
captured on the strips of the line probe assay may be a
possible limitation in the use of this technique.
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